{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2019)
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2019)
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2019)
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2019)
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1999)
First approved in 1953
Source:
BLA103915
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00981630: Phase 2 Interventional Completed Japanese Encephalitis
(2004)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE